Perioperative Immunotherapy for Resectable Limited-Stage SCLC

Prior treatment

• Receiving systemic corticosteroid therapy within 14 days prior to the first dose of study drug;
• Previous radiotherapy, chemotherapy, immunotherapy, surgery, or other systemic treatments;
• Any active malignancy within 2 years prior to enrollment;
• Active or previously recorded autoimmune or inflammatory diseases before enrollment;
• Active bleeding disorders within ≤6 months prior to administration of the study drug, including gastrointestinal bleeding evidenced by hematemesis, severe hemoptysis, or melena;

Other illness

• Tumor histopathology indicates non-small cell lung cancer (NSCLC);
• Any history of interstitial lung disease (ILD) (including pulmonary fibrosis or radiation pneumonitis), current ILD, or suspicion of such diseases based on imaging during screening;
• Uncontrolled or significant cardiovascular disease at the time of enrollment;
• History of active primary immunodeficiency disorders;
• Presence of active infections;
• Any condition that the investigator deems makes the patient unsuitable for participation in the study.

Other

• Presence of clinically inactive or active brain metastases;
• Women who are pregnant, breastfeeding, or planning to become pregnant during the study period;
• Non-healing wounds, active peptic ulcers, or fractures;

• Able to provide written informed consent and understand and agree to comply with the study requirements and assessment schedule;
• Aged 18-75 years at the time of signing the informed consent form;
• Pathologically (histologically or cytologically) confirmed diagnosis of small cell lung cancer;
• Limited-stage disease (stage IIB-IIIB according to AJCC 8th edition) assessed by bronchoscopy, PET-CT, endobronchial ultrasound (EBUS), mediastinoscopy, or percutaneous biopsy, deemed resectable with curative intent (R0 resection) by the investigator.
  • TNM staging includes T3-4 (N0 only) or N1-2 (any T) and M0, where T4 is limited to tumors \>7 cm in diameter; Patients with tumors invading the diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina or having separate tumor nodules in different ipsilateral lobes are excluded. N2 is limited to single station and non-bulky.
• No prior radiotherapy, chemotherapy, immunotherapy, surgery or other systemic treatments;
• ECOG PS score of 0-1;
• Expected survival must be \>3 months;
• Adequate bone marrow reserve and organ function within 30 days prior to enrollment meeting criteria for receiving platinum-based doublet chemotherapy;
• No contraindications for immunotherapy.